ARTICLE SUMMARY:
Medtronic is leading the way when it comes to embracing value-based care and risk-sharing agreements in the diabetes device arena. And, according to Suzanne Winter, group VP of the Americas at Medtronic Diabetes, the company is anticipating substantial upside from this strategy. It has already established risk-sharing/preferred supplier agreements with two of the largest US payors and expects to announce more such deals, with payors, providers, and employers, in the near future.
Medtronic plc is taking a proactive approach when it comes to embracing value-based healthcare models in the medtech marketplace, and its substantial moves in the diabetes care arena are a case in point. (See “Diabetes Devices: A Market in Transition,” MedTech Strategist, October 12, 2017.)
